Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation

被引:159
作者
Gottlieb, Jens [1 ]
Szangolies, Jennifer [1 ]
Koehnlein, Thomas [1 ]
Golpon, Heiko [1 ]
Simon, Andre [2 ]
Welte, Tobias [1 ]
机构
[1] Hannover Med Sch, Dept Resp Med OE6870, D-30625 Hannover, Germany
[2] Hannover Med Sch, Dept Thorac & Cardiovasc Surg, D-30625 Hannover, Germany
关键词
lung transplantation; bronchiolitis obliterans syndrome; airway neutrophilia; azithromycin;
D O I
10.1097/01.tp.0000295981.84633.bc
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Bronchiolitis obliterans syndrome (BOS) is a major cause of morbidity and mortality after lung transplantation (LTx). Macrolides are a promising treatment option for BOS. The objective of this study was to determine long-term results of azithromycin treatment in patients with BOS. Variables to predict treatment response were evaluated. Methods. An observational study in a single center was performed. Eighty-one adult LTx-recipients (single, double, combined, and re-do) with at least BOS stage 0p (mean forced expired volume in I second [FEV1] 55 +/- 19%) were included. For treatment, 250 mg of oral azithromycin was administered three times per week. Results. Twenty-four of 81 (30%) patients showed improvement in FEV1 after 6 months, 22/24 already after 3 months of treatment. By univariate analysis, responders at 6 months had higher pretreatment bronchoalveolar lavage (BAL) neutrophils (51 +/- 29 vs. 21 +/- 24%). A cutoff value of < 20% in pretreatment BAL had a negative predictive value of 0.91 for treatment response. Thirty-three patients (40%) showed disease progression during follow-up (491 +/- 165 days). Cox regression analysis identified a rapid pretreatment decline in FEV1 and comedication of an mammalian target of rapamycin inhibitor as positive predictors and proton pump inhibitor comedication and a treatment response at 3 months as negative predictors for disease progression (FEV1 < 90% baseline). Conclusions. Azithromycin can improve airflow limitation in a significant proportion of patients with even long-standing BOS. The majority of responders were identified after 3 months of treatment. Results indicate the predictive value of BAL neutrophilia for treatment response and pretreatment course of FEV1 as a variable for disease progression. Beneficial effects on gastroesophageal reflux disease may be a mechanism of action.
引用
收藏
页码:36 / 41
页数:6
相关论文
共 24 条
  • [1] Post-transplant bronchiolitis obliterans
    Boehler, A
    Estenne, M
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2003, 22 (06) : 1007 - 1018
  • [2] Effect of azithromycin on the severity of bronchial hyperresponsiveness in patients with mild asthma
    Ekici, A
    Ekici, M
    Erdemoglu, AK
    [J]. JOURNAL OF ASTHMA, 2002, 39 (02) : 181 - 185
  • [3] Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial
    Equi, A
    Balfour-Lynn, IM
    Bush, A
    Rosenthal, M
    [J]. LANCET, 2002, 360 (9338) : 978 - 984
  • [4] Bronchiolitis obliterans syndrome 2001: An update of the diagnostic criteria
    Estenne, M
    Maurer, JR
    Boehler, A
    Egan, JJ
    Frost, A
    Hertz, M
    Mallory, GB
    Snell, GI
    Yousem, S
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2002, 21 (03) : 297 - 310
  • [5] Maintenance azithromycin therapy for bronchiolitis obliterans syndrome - Results of a pilot study
    Gerhardt, SG
    McDyer, JF
    Girgis, RE
    Conte, JV
    Yang, SC
    Orens, JB
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 168 (01) : 121 - 125
  • [6] Gastroesophageal reflux disease in lung transplant recipients
    Hadjiliadis, D
    Davis, RD
    Steele, MP
    Messier, RH
    Lau, CL
    Eubanks, SS
    Palmer, SM
    [J]. CLINICAL TRANSPLANTATION, 2003, 17 (04) : 363 - 368
  • [7] Acute and chronic onset of bronchiolitis obliterans syndrome (BOS): Are they different entities?
    Jackson, CH
    Sharples, LD
    McNeil, K
    Stewart, S
    Wallwork, J
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2002, 21 (06) : 658 - 666
  • [8] Anti-inflammatory effects of macrolides in lung disease
    Jaffé, A
    Bush, A
    [J]. PEDIATRIC PULMONOLOGY, 2001, 31 (06) : 464 - 473
  • [9] Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin
    Kudoh, S
    Azuma, A
    Yamamoto, M
    Izumi, T
    Ando, M
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1998, 157 (06) : 1829 - 1832
  • [10] Safety, toleration, and pharmacokinetics of intravenous azithromycin
    Luke, DR
    Foulds, G
    Cohen, SF
    Levy, B
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (11) : 2577 - 2581